Medical Letter on the CDC & FDA
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC & FDA
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Anthrax Therapy
New anthrax therapy study findings recently were published by researchers at Los Alamos National Laboratory, Biosciences Division
November 9th, 2008
A new study, 'A dual-purpose protein ligand for effective therapy and sensitive diagnosis of anthrax,' is now available. "This article reports the design of a bivalent protein ligand with dual use in therapy and diagnosis of anthrax caused by Bacillus anthracis. The ligand specifically binds to PA and thereby blocks the intracellular delivery of LF and EF toxins that, respectively, cause cell lysis and edema," scientists in the United States report. "The ligand is a chimeric scaffold with two PA-binding domains (called VWA) linked to an IgG-Fc frame. Molecular modeling and binding measurements reveal that the VWA-Fc dimer binds to PA with high affinity (K(D)=0.2...
Source: Medical Letter on the CDC & FDA (2008-11-09)
|
